Valuation: Proteomics International Laboratories Ltd

Market Cap 19M 13.21M 11.56M 10.66M 9.85M 18.68M 1.26B 127M 50.02M 621M 49.61M 48.53M 2.13B P/E 2024
-17.4x
P/E 2025 -5.38x
Enterprise Value 8.24M 5.73M 5.01M 4.62M 4.27M 8.1M 546M 55.23M 21.69M 269M 21.51M 21.04M 925M EV / Sales 2024
33.2x
EV / Sales 2025 12.8x
Free-Float
74.46%
Yield 2024 *
-
Yield 2025 -
1 day+20.59%
1 week+28.12%
Current month+78.26%
1 month+64.00%
3 months-8.89%
6 months-69.17%
Current year-68.70%
1 week 0.15
Extreme 0.15
0.22
1 month 0.1
Extreme 0.098
0.22
Current year 0.1
Extreme 0.098
0.86
1 year 0.1
Extreme 0.098
0.86
3 years 0.1
Extreme 0.098
1.4
5 years 0.1
Extreme 0.098
1.4
10 years 0.1
Extreme 0.098
1.48
Manager TitleAgeSince
Chief Executive Officer - 2026-01-18
Director of Finance/CFO - 2026-04-16
Director of Finance/CFO - 2021-07-11
Director TitleAgeSince
Director/Board Member - 2017-11-21
Chairman 56 -
Director/Board Member - 2024-11-07
Date Insider Type Main position Quantity % Market Cap.
24-11-20Free

Founder

1,000,000 0.7633%
24-11-20Free

Founder

800,000 0.6107%
24-11-20Free

Founder

800,000 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
+20.59%+28.12%-54.95%-76.70% 19.5M
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-2.95%+2.71%+18.52%+461.59% 25.63B
-1.45%-2.44%-19.56%-14.70% 23.51B
+2.43%+5.86%+46.56%+0.42% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+10.46%+47.66% - 14.13B
-0.72%+1.98%+25.37%+196.96% 14.35B
Average +1.40%+1.67%+43.49%+122.41% 24.22B
Weighted average by Cap. -1.07%+0.29%+54.92%+137.53%

Financials

2024 2025
Net sales 3.28M 2.28M 1.99M 1.84M 1.7M 3.22M 217M 21.97M 8.63M 107M 8.56M 8.37M 368M 3.31M 2.3M 2.02M 1.86M 1.72M 3.26M 220M 22.21M 8.72M 108M 8.65M 8.46M 372M
Net income -6.38M -4.44M -3.88M -3.58M -3.3M -6.27M -423M -42.75M -16.79M -208M -16.65M -16.29M -716M -8.11M -5.64M -4.94M -4.55M -4.21M -7.98M -538M -54.41M -21.37M -265M -21.19M -20.73M -912M
Net Debt -6.32M -4.4M -3.85M -3.55M -3.28M -6.22M -420M -42.4M -16.65M -207M -16.52M -16.16M -710M -10.76M -7.48M -6.55M -6.04M -5.58M -10.58M -714M -72.14M -28.33M -352M -28.1M -27.49M -1.21B
Logo Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
Employees
-
Date Price Change Volume
26-07-10 A$0.2050 +20.59% 1,174,994
26-07-09 A$0.1700 +6.25% 509,126
26-07-08 A$0.1600 +3.23% 1,697,784
26-07-07 A$0.1550 -11.43% 211,911
26-07-06 A$0.1750 -12.50% 1,732,111

Annual profits - Rate of surprise